Nevanimibe

• Description :

  Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer[1].

• Product Name Alternative :

  PD-132301; ATR-101

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Acyltransferase; Apoptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Nevanimibe.html

• Purity :

  98.99

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C(NCC1(C2=CC=C(N(C)C)C=C2)CCCC1)NC3=C(C(C)C)C=CC=C3C(C)C

• Molecular Formula :

  C27H39N3O

• Molecular Weight :

  421.62

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]LaPensee CR, et al. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology. 2016 May;157 (5) :1775-88.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  ACAT1; ACAT2

• Citation 01 :

  Cell Rep. 2022 Nov 29;41 (9) :111724.|Mol Cell Endocrinol. 2024 Dec 1:594:112385.|Structure. 2021 Dec 2;29 (12) :1410-1418.e4.

• CAS Number :

  [133825-80-6]